ATS View
한국어

Xcell Therapeutics KRX:373110KOSDAQ

엑셀세라퓨틱스 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h4
Articles, 7 days4
DART filings, 7 days1
Articles tracked4since Sep 11

In Q2 2026, Xcell Therapeutics reported revenue of ₩1.9bn, up 775.4% year on year, and an operating loss of ₩2.8bn. Xcell Therapeutics (엑셀세라퓨틱스) appeared in 4 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Sep 15 with 4 articles. It was most often mentioned alongside ImmuneOncia Therapeutics.

Xcell Therapeutics quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩1.9bn+775.4%−₩2.8bn−₩2.8bn
Q1 2026₩1.0bn+209.8%−₩2.9bn−₩2.9bn
Q4 2025 derived₩1.1bn+123.2%−₩3.3bn−₩3.4bn
Q3 2025₩335m-26.9%−₩2.4bn−₩2.3bn
Q2 2025₩221m-53.7%−₩2.7bn−₩2.7bn
Q1 2025₩330m-36.8%−₩2.6bn−₩2.6bn
Q4 2024 derived₩477m-2.2%−₩2.5bn−₩2.4bn
Q3 2024₩458m+54.0%−₩2.7bn−₩2.7bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.

Xcell Therapeutics top stories 2 weeks, by number of outlets

  1. 1
    엑셀세라퓨틱스 "연내 신규 배지 4종 출시"
    2 outlets · 2 articlesFirst report Sep 15 08:38 아시아경제
  2. 2
    엑셀세라퓨틱스, 신제품 4종으로 배지 라인업 확대
    1 outlets · 1 articlesFirst report Sep 15 09:33 한스경제
  3. 3
    [BIO톡]엑셀세라퓨틱스, CGT 배지 4종으로 글로벌 매출 확대 정조준 外 이뮨온시아·베르티스
    1 outlets · 1 articlesFirst report Sep 15 10:28 글로벌경제신문ImmuneOncia Therapeutics

Latest Xcell Therapeutics news Korean headlines